Navigation Links
Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis

improved, unchanged and worsened by 64.3%, 21.4% and 14.3%, respectively. The EDSS for a 0.5 point sustained (no change over 3 months) effect was improved, unchanged and worsened by 42.9%, 42.9% and 14.2%, respectively. The EDSS for a 1.0 sustained effect was improved, unchanged and worsened by 28.6%, 57.1% and 14.3%, respectively.

Brian Loftus, M.D. of Bellaire Neurology, the Principal Investigator of these Tovaxin studies, commented, "This data, combined with prior data presented on myelin reactive T-cell frequencies and ARR reductions, laid the ground work for the placebo-controlled Tovaxin IIb clinical trial (TERMS). We have shown that myelin reactive T-cells can be identified and used to produce T-cell vaccine which effectively induces the depletion of an individual's autoreactive T-cells and results in positive clinical outcomes. I anticipate Tovaxin will usher in the age of personalized therapy for MS."

David McWilliams, president and chief executive officer of Opexa, said, "We are particularly encouraged by the data from this extension trial which indicates that subjects previously treated with T-cell vaccine can be safely and effectively retreated with Tovaxin. This outcome is important to our planned extension trial for subjects currently enrolled in our TERMS trial following the one year core study time period." In addition, the effectiveness data in RRMS subjects across the two Phase I/II trials indicate strongly positive outcomes in both ARR and EDSS improvements following Tovaxin therapy."

About TERMS

The Tovaxin Phase IIb clinical study will include 150 patients in a multicenter, randomized, double blind, placebo-controlled trial designed primarily to evaluate the efficacy, safety and tolerability of the Tovaxin T-cell vaccination with clinically isolated syndrome (CIS) and relapsing-remitting MS (RR-MS) patients. A total of 100 patients will receive Tovaxin, while 50 will receive placebo. The study is designed as a two-ar
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
2. Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting
3. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
(Date:8/21/2014)... 2014 /CNW/ - Bedrocan Cannabis Corp., previously Bedrocan Canada ... its Board of Directors, enhancing executive oversight and ... a leading licensed producer of medicinal cannabis in ... 13 years, experience in producing and supplying government-regulated ... Canada. As previously announced in ...
(Date:8/21/2014)... (NASDAQ: CYBX ) today announced results for the ... 1   Operating results for the first quarter ... 2014, and other achievements, include: , Worldwide net product ... Strong international net sales of $13.2 million, an increase of ... product sales reached a new high of $58.8 million, an ...
(Date:8/21/2014)... 2014 Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a ... medicine, announced today the appointments of Andrew ("Andy") Arno ... Board of Directors. With these additions, the Asterias Board ... are independent. Andy Arno , 55, ... companies. He is currently Managing Director of Emerging Growth ...
Breaking Medicine Technology:Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4
... SANTA MARIA, Calif., Feb. 14, 2011 Hardy Diagnostics, ... the release of HardyCHROM™ SS, a highly selective chromogenic ... for the isolation and differentiation of Salmonella ... two pathogens can be easily distinguished from non-pathogenic enteric ...
... MedQuist Holdings Inc. (Nasdaq: MEDH ), formerly ... documentation solutions for the U.S. healthcare system, today announced ... shares of its common stock.  The shares began trading ... under the ticker symbol MEDH. In ...
Cached Medicine Technology:The Only Chromogenic Medium That Detects Both Salmonella and Shigella! 2MedQuist Holdings Inc. Announces Closing of Its Initial U.S. Public Offering and Acquisition of Additional Shares of MedQuist Inc. 2MedQuist Holdings Inc. Announces Closing of Its Initial U.S. Public Offering and Acquisition of Additional Shares of MedQuist Inc. 3
(Date:8/21/2014)... Line: Patients with advanced laryngeal cancer appear to ... surgery than nonsurgical chemoradiation. , Author: Uchechukwu C. ... Medicine at Mount Sinai, New York, and colleagues. ... laryngeal cancer are diagnosed each year and squamous ... these tumors. Prior to 1991, total surgical removal ...
(Date:8/21/2014)... Improv performers from Fun House Theatre and ... Silverado Turtle Creek memory care community in Dallas. The ... from ages 10 to 16, delivers a groundbreaking and ... The troupe's philosophy is that improv is based on ... touch audiences regardless of their circumstance — including bringing ...
(Date:8/21/2014)... have pinpointed the environmental source of fungal infections that ... decades. It literally grows on trees. , The discovery ... girl, who spent the summer gathering soil and tree ... infections of the fungus named Cryptococcus gattii ... encompasses a number of species including C. gattii ...
(Date:8/21/2014)... California (PRWEB) August 21, 2014 The ... initial plans for entertainment and programming for its inaugural ... On Sunday, October 12, 2014, from 11 a.m. to ... closed to all cars and the downtown will be ... activities, curated by Community Arts Resources (CARS), for all ...
(Date:8/21/2014)... Aug. 21, 2014 (HealthDay News) -- Not only is eating ... save them hundreds of health-care dollars a year, a new ... professor of public health sciences at Wake Forest Baptist Medical ... and obese type 2 diabetes patients. Participants ... assigned to either an intensive "lifestyle change program" focused on ...
Breaking Medicine News(10 mins):Health News:Surgery associated with better survival for patients with advanced laryngeal cancer 2Health News:Unicorn Clearance Improv Troupe Brings Laughter to Residents with Dementia at Silverado Memory Care 2Health News:Fungus deadly to AIDS patients found to grow on trees 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 3Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 4Health News:Getting Healthier a Big Money-Saver for People With Diabetes 2
... PURCHASE, N.Y., March 30 Nutrition 21 is ... and Chief Executive Officer, has been elected to ... Products Association (CHPA). CHPA is a 128-year ... over-the-counter medicines and nutritional supplement products. Members ...
... Year According to the Better Sleep CouncilDALLAS, March 30 ... is usually one of the first things people scrimp on ... turbulent economy, nearly 30 percent of Americans lose sleep ... a 2009 Sleep in America poll by the National Sleep ...
... A health insurance protocol intended to ... barriers that lead people to receive less of needed ... result, patients ultimately require more -- and more costly ... plan members to try a first-line medication before they ...
... of chronic illnesses in Europe and the consequent ... has amplified the need for equipment that measure ... This rise in the number of people requiring ... and transducers.(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )New analysis from ...
... Q-Stress and Q-Tel cardiac rehab to healthcare information ... CSCX ), a global leader in ... today added DICOM connectivity to its Quinton Q-Stress ... rehabilitation system. "With DICOM and HL7 technologies, Cardiac ...
... Kachmann teaches how the connection between mind, body ... Ind., March 30 For residents of Ft. ... Kachmann Mind Body Institute ( www.kachmannmindbody.com ) noted ... health and the arts. Now, having retained award-winning ...
Cached Medicine News:Health News:Nutrition 21's President and CEO, Elected to the Consumer Healthcare Products Association Board 2Health News:Nutrition 21's President and CEO, Elected to the Consumer Healthcare Products Association Board 3Health News:It Pays to Sleep: Prioritize Rest to Boost Health, Morale and Revenue 2Health News:It Pays to Sleep: Prioritize Rest to Boost Health, Morale and Revenue 3Health News:Thomson Reuters Study Finds Step Therapy Programs May Increase Overall Healthcare Costs for Employers 2Health News:Thomson Reuters Study Finds Step Therapy Programs May Increase Overall Healthcare Costs for Employers 3Health News:Expanding Patient Population Creates a Huge Market for Invasive Pressure Monitoring and Hemodynamic Monitoring, Finds Frost & Sullivan 2Health News:Expanding Patient Population Creates a Huge Market for Invasive Pressure Monitoring and Hemodynamic Monitoring, Finds Frost & Sullivan 3Health News:Expanding Patient Population Creates a Huge Market for Invasive Pressure Monitoring and Hemodynamic Monitoring, Finds Frost & Sullivan 4Health News:Cardiac Science Connects to EMR, HIS, PACS Systems Using DICOM and HL7 Technologies 2Health News:Cardiac Science Connects to EMR, HIS, PACS Systems Using DICOM and HL7 Technologies 3Health News:Cardiac Science Connects to EMR, HIS, PACS Systems Using DICOM and HL7 Technologies 4Health News:Dr. Rudy Kachmann, Neurosurgeon, Author, Lecturer & Founder of Kachmann Mind Body Institute Selects TransMedia Group as Agency of Record 2
Nidek offers 3-Dx Digital stereo camera to provide a complete and comprehensive digital imaging platform....
Measurement of progressive multi-focal lenses is fast and easy with the CLM-3000 auto-lensmeter. The data is represented in a simple to understand bar graphic display....
Auto Lensmeter LM-970...
Autolensmeter with black/white monitor and no internal printer....
Medicine Products: